Skip to content
Product safetyFDAUnited StatesImports

Advisory Committee; Cellular, Tissue, and Gene Therapies Advisory Committee; Renewal

14 October 2026

In plain English

FDA renews its Cellular, Tissue, and Gene Therapies Advisory Committee for two more years, with the new charter effective until October 28, 2028.

Read the official notice
Topic
Product safety
Regulator
FDA
Published
14 October 2026
For
Imports
Where it applies
United States
Source
FDA (Food and Drug Administration)

From the notice

The Food and Drug Administration (FDA) is announcing the renewal of the Cellular, Tissue, and Gene Therapies Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Cellular, Tissue, and Gene Therapies Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the October 28, 2028, expiration date.

Olive tells you which of these hit your products.

Olive reads every change like these against your own products, codes and trade lanes, whether you import, export or both, and drafts the update to your compliance program for your approval. Nothing changes without you.

Get startedLive demo

Olivra lists official notices for information only. It is not legal advice, and Olive is not a lawyer or a licensed customs broker. The official text at the source is what counts.

More from FDA

See everything Olive monitors